Trillium Therapeutics (TRIL) –
-
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
-
Form 15-12B Trillium Therapeutics
-
Form EFFECT Trillium Therapeutics
-
Form EFFECT Trillium Therapeutics
-
Form 4 Trillium Therapeutics For: Nov 17 Filed by: Walker Paul Edward
-
Form 4 Trillium Therapeutics For: Nov 17 Filed by: Pucci Paolo
-
Form 4 Trillium Therapeutics For: Nov 17 Filed by: Myers Scott Dunseth
-
Form 4 Trillium Therapeutics For: Nov 17 Filed by: Harrison Rosemary
-
Form 4 Trillium Therapeutics For: Nov 17 Filed by: BESHAR LUKE M
-
Form 4 Trillium Therapeutics For: Nov 17 Filed by: Parsons James T.
-
Form 4 Trillium Therapeutics For: Nov 17 Filed by: Kamarck Michael E.
-
Form 4 Trillium Therapeutics For: Nov 17 Filed by: Looker Benjamin
-
Form 4 Trillium Therapeutics For: Nov 17 Filed by: MACKEY CATHERINE J
-
Form 4 Trillium Therapeutics For: Nov 17 Filed by: Bruns Ingmar
-
Form 4 Trillium Therapeutics For: Nov 17 Filed by: Petrova Penka
-
Form 4 Trillium Therapeutics For: Nov 17 Filed by: Uger Robert
-
Form 4 Trillium Therapeutics For: Nov 17 Filed by: TAYTON-MARTIN HELEN KATRINA
-
Form 4 Trillium Therapeutics For: Nov 17 Filed by: Skvarka Jan
-
Form SC 13D/A Trillium Therapeutics Filed by: Growth Equity Opportunities V, LLC
-
Form S-8 POS Trillium Therapeutics
-
Form S-8 POS Trillium Therapeutics
-
Form POSASR Trillium Therapeutics
-
Form POS AM Trillium Therapeutics
-
Form POS AM Trillium Therapeutics
-
Form 8-K Trillium Therapeutics For: Nov 17
-
Form 25-NSE Trillium Therapeutics Filed by: Nasdaq Stock Market LLC
-
Benchmark Downgrades Trillium Therapeutics (TRIL) to Hold
-
Increasing unusual put option volume: GGPI MQ INDA TRIL
-
Form 8-K Trillium Therapeutics For: Nov 15
-
Form SC 13G/A Trillium Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 10-Q Trillium Therapeutics For: Sep 30
-
Form 8-K Trillium Therapeutics For: Oct 28
-
Trillium Therapeutics Receives Final Court Order Approving Arrangement
-
Frazier Healthcare Partners Announces Several Promotions on Life Sciences Team
-
Frazier Healthcare Partners Closes Oversubscribed $830 Million Life Sciences Public Fund
-
Form 8-K Trillium Therapeutics For: Oct 26
-
Trillium Therapeutics (TRIL) Shareholders Approve Takeover by Pfizer
-
Trillium Securityholders Approve Acquisition by Pfizer
-
Form DEFA14A Trillium Therapeutics
-
Form 8-K Trillium Therapeutics For: Oct 19
-
Form 8-K Trillium Therapeutics For: Oct 13
-
Form DEFA14A Trillium Therapeutics
-
Form DEFA14A Trillium Therapeutics
-
Form 8-K Trillium Therapeutics For: Oct 12
-
Form DEFA14A Trillium Therapeutics
-
Form DEFM14A Trillium Therapeutics
-
Increasing unusual option volume: TRIL PROG FROG ATER MCFE ISEE
-
Form PREM14A Trillium Therapeutics For: Sep 13
-
Form SC 13D/A Trillium Therapeutics Filed by: Growth Equity Opportunities V, LLC
-
Increasing unusual option volume: TRIL GES COMM ACM URBN DKS
Back to TRIL Stock Lookup